Study With SCB-313 (Recombinant Human TRAIL-Trimer Fusion Protein) for Treatment of Malignant Pleural Effusions
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and
PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via
intrapleural injection (SAD) and once daily over 2 to 3 days (MAD)for the treatment of cancer
patients with symptomatic malignant pleural effusions requiring drainage.